-
Baekje: recommended by the National Institute of Health and Clinical Optimization in the UK for the treatment of adult patients with chronic lymphocytic leukemia
On October 20th, Baekje announced that the National Institute of Health and Clinical Optimization (NICE) in the UK has released a final evaluation document recommending the company's product, Baekje& ... -
Lilly Pharmaceuticals: Our company's treatment for lymphocytic leukemia, Jaypirca, has been approved by the FDA
Lilly Pharmaceuticals claims that its treatment for lymphocytic leukemia, Jaypirca (pirobrutinib/pirobrutinib), has been approved by the US Food and Drug Administration (FDA).